Does BPC-157 heal injuries?
The claim
BPC-157, a synthetic peptide derived from a protein in gastric juice, speeds the healing of tendon, ligament, muscle and gut injuries when injected or taken orally.
The case for
“especially when you consider the fact that this stuff can permanently heal and strengthen weak joints, connective tissues, muscles and gut.”
Ben Greenfield, health consultant, speaker and author · 2016-05-16 · source
“From sprains and tendonitis to joint instability, BPC-157 offers a safe and powerful alternative.”
Revolution Health & Wellness, clinic in Sapulpa, Oklahoma · 2025-05-28 · source
The case against
“They sit in a more uncomfortable middle ground: interesting biology, intriguing findings in animal studies and, realistically, no convincing proof that they promote musculoskeletal healing in people.”
Flynn McGuire, resident in physical medicine and rehabilitation, University of Utah · 2026-05-07 · source
“However, there are no human clinical trials establishing efficacy for the use of BPC-157 for any diagnosis or treatment.”
U.S. Anti-Doping Agency (USADA), athlete education page · 2026-08-10 · source
Quotes are short extracts, in the speakers' own words, about the claim or the evidence; each links to where it was said. Inclusion is not endorsement.
What the sources say
Evidence for this claim 3/10 · early human evidence
BPC-157 is a synthetic peptide that is not approved as a medicine by the FDA or any other health authority. A 2025 systematic review found 36 studies of it in orthopaedic sports medicine: 35 in animals or cells and one in people, a retrospective telephone survey of 16 knee-pain patients at one clinic with no comparison group. A 2026 systematic review found three human studies with 30 participants in all, none of them controlled, and rated the certainty of the evidence very low; no randomised trial of BPC-157 for any injury has been published. The FDA says it lacks the information to know whether BPC-157 would cause harm in people, and the peptide is prohibited in sport under the WADA list. A draft HHS policy posted in October 2026 eases access through compounding pharmacies without approving the peptide.
Scores healing of tendon, ligament, muscle and gut injuries in people: a large animal literature, three small uncontrolled human studies and no randomised trials.
The record
- Systematic review2025 · A 2025 systematic review in HSS Journal found 36 eligible studies on BPC-157 in orthopaedic sports medicine, 35 of them preclinical and one clinical (a retrospective knee-pain series), and found no clinical safety data. source
- Systematic review2026 · A 2026 PROSPERO-registered systematic review (Acta Orthopaedica Belgica) found only three human studies with 30 participants in total, all uncontrolled and of poor quality, rated the certainty of evidence very low, and concluded BPC-157 should not be used clinically outside regulated trials. source
- Trial2021 · The only human study of BPC-157 for a musculoskeletal complaint (2021) was a retrospective phone survey of 16 knee-pain patients at one Florida clinic, with no control group and no standardised outcome measures; 14 reported relief. source
- Trial2025 · A 2025 intravenous safety pilot gave BPC-157 to two adults and reported no measured changes in heart, liver, kidney, thyroid or glucose markers; it did not assess healing. source
- Regulator2026-04-22 · The FDA's list of bulk substances that may present significant safety risks in compounding (page current as of 2026-04-22) states that the agency has no, or only limited, safety information on BPC-157 and lacks sufficient information to know whether it would cause harm in humans. source
- Regulator2026-08-10 · USADA states that BPC-157 is prohibited under the WADA Prohibited List category S0 (non-approved substances) and is not approved for human clinical use by the FDA or any other health authority. source
- Regulator2026-10-28 · On 2026-10-28 HHS posted a draft policy directing the FDA not to take enforcement action against specialty pharmacies compounding a half-dozen peptides including BPC-157, after an advisory committee voted 8-6 for expanded access in July 2026 against the recommendation of FDA scientists; the substances remain unapproved. source
Sources: bengreenfieldlife.com, revolutionhealth.org, theconversation.com, usada.org, pubmed.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, fda.gov, nbcboston.com, theconversation.com, pubmed.ncbi.nlm.nih.gov.
Compiled by the Alivewire editors from the sources above, ; evidence last checked . This page describes the published evidence on a claim; it makes no judgement about the people who make it. We rely on sources we consider reputable but do not independently verify the facts they report. Not medical advice.
If you are quoted here and believe we have misstated your position, or if the evidence has moved, please tell us; an editor checks every report and corrects the page when it holds. How claims pages work.